miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

An Investor's Guide to 2026

View original at nasdaq.com
An Investor's Guide to 2026 In this podcast, Motley Fool analyst Emily Flippen and contributors Travis Hoium and Lou Whiteman discuss: The AI trade.How the economy is doing.Where certain stocks might be headed…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Nvidia will beat market in 2026 despite potential slowdown, needs only ~8% vs historical 78%+

    80% confidence
  • Stock market is not the economy - Wall Street doesn't track with Main Street

    80% confidence
  • AI compute more expensive than traditional compute, impacting margins

    80% confidence
  • Alphabet leader position sustained, advertising won't collapse

    80% confidence
  • Intel will have tepid beat, backed by US government, closed Nvidia investment

    80% confidence
  • Fed members doubt reported economic data

    80% confidence
  • The novelty is over. The magic has gone

    80% confidence
  • Buy metal ETFs, not mining stocks - mining stocks historically poor performers

    80% confidence
  • OpenAI has $1.5 trillion spending plans and desperately needs advertising model

    80% confidence
  • Target has turnaround potential if discretionary spending returns

    80% confidence
  • Alphabet has 75% ad revenue at risk, advertising falling off cliff

    80% confidence
  • Advertising is midterm game for AI

    80% confidence
  • Nike has no innovation desire, competition from ON Holdings eating lunch

    80% confidence
  • Chipotle has easier comps post-pandemic with low expectations

    80% confidence
  • Intel is not chip space leader

    80% confidence
  • Tesla facing EV demand declining, tax credits rolled over, international competition

    80% confidence
  • 2026 is year of agents - specialization over scale

    80% confidence
  • Disruption implies being taken aback by something you didn't see coming. AI isn't disruptive because companies could see the future

    80% confidence
  • AI progress is incremental, not flashy - making tasks 10% better across many small automations

    80% confidence
  • Apple will benefit from AI integration, disciplined capital management, and upgrade cycle

    80% confidence
  • Zero-sum advertising market: finite budgets redistributed among platforms

    80% confidence
  • Top 10% spenders account for ~50% of spending in K-shaped economy

    80% confidence
  • Lululemon has proxy fight/new CEO momentum, merchandising fixable

    80% confidence
  • Palantir trades at 111x sales with no fundamental change in government spending expected

    80% confidence
  • Airbnb changed upfront payment policy hurting high-margin interest income, declining interest rates negatively impact

    80% confidence
  • US may have been losing jobs through majority of 2025

    80% confidence
  • Target turnaround takes more than 1 year, retail too tough

    80% confidence
  • Chipotle faces too crowded fast-casual space

    80% confidence
  • Nvidia will lose to market because historically largest company doesn't stay largest in 3-year period

    80% confidence
  • 2026 is the year where consumers start seeing ads in ChatGPT

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
An Investor's Guide to 2026 — Source | Via News | es.VIA.NEWS